Blood Typing Market Size To Reach $3.83 Billion By 2030

Blood Typing Market Growth & Trends

The global blood typing market size is anticipated to reach USD 3.83 billion by 2030 and is projected to grow at a CAGR of 10.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. This growth is fueled by the increasing usage of blood group typing in forensic sciences and prenatal testing, alongside the rising number of blood transfusions necessitated by road accidents and emergencies.

Blood group typing is a critical process that identifies the O, A, B, and AB groups, ensuring compatibility between donors and recipients and determining the Rh factor. This is particularly crucial in prenatal testing to prevent Hemolytic Disease of the Newborn (HDN), a condition that can be fatal if not detected. The market's growth is also supported by the growing number of road accidents and emergencies, which necessitate transfusions, and the increasing number of donations.

According to CDC, road accidents claim approximately 1.35 million lives annually, highlighting the critical role of blood group typing in ensuring safe transfusions. The advanced medical infrastructure in many countries, including increased storage capacities in hospitals, further supports the market's growth by facilitating the storage and availability of blood samples for typing and cross-matching. The rise in accidents and trauma cases requiring blood transfusions is another key factor for the market growth. The urgent need for transfusion in patients requiring surgical intervention also acts as a key driving factor.

Furthermore, prenatal testing, which requires blood group typing to manage potential complications, is another significant driver. The need for accurate blood group typing in pregnant women to prevent HDN is anticipated to further drive the market's growth. In addition, the increasing demand for blood group typing in forensic sciences contributes to the market’s expansion.

Moreover, market players are striving to innovate and introduce new initiatives that contribute to the advancement of diagnostic technologies. These initiatives play a pivotal role in shaping the dynamics of the market, driving improvements in patient care, and addressing the evolving needs of healthcare providers. By leveraging their expertise and resources, market players introduce innovative solutions that enhance efficiency, accuracy, and accessibility within the healthcare ecosystem. For instance, in March 2022, Quotient Limited obtains CE Mark for MosaiQ Extended Immunohematology Microarray, enhancing blood typing capabilities with Antibody Screening, Antigen Typing, and ABO grouping on a single platform, promising improved workflow and clinical value. Such initiatives market players contribute to the broader healthcare market, with a focus on advancements in diagnostic technologies.

 Request a free sample copy or view report summary: Blood Typing Market Report

Blood Typing Market Report Highlights

• The reagents and consumables segment led the market with the largest revenue share of 71.7% in 2023 and is anticipated to grow at the lucrative CAGR over the forecast period, owing to extensive R&D initiatives being undertaken by major players for development of novel kits

• Based on test type, the antibody screening segment led the market with the largest revenue share of 38.6% in 2023, whereas HLA typing segment is estimated to grow at the fastest CAGR over the forecast period, owing to the development of advanced and innovative diagnostics in the market

• Based on technique, the PCR based and microarray based segment led the market with the largest revenue share of 52.1% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period

• Based on application, the diagnostic testing segment led the market with the largest revenue share of 54.1% in 2023. The organ transplants segment is estimated to grow at the fastest CAGR over the forecast period

• Based on end-use, the diagnostic laboratories segment led the market with the largest revenue share of 43.4% in 2023, owing to large number of tests being done at the facilities

• North America dominated the market with the revenue share of 44.6% in 2023, owing to factors such as advanced healthcare infrastructure, rising prevalence of chronic diseases, and favorable regulatory environment

Blood Typing Market Segmentation

Grand View Research has segmented the global blood typing market report based on product & services, test type, technique, application, end-use, and region:

Blood Typing Product & Services Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

• Reagents & Consumables

  • RBC Reagents

  • Antisera Reagents

  • Anti Human Globulin Reagents

  • Blood Saline Reagents

• Services

Blood Typing Test Type Outlook (Revenue, USD Million, 2018 - 2030)

• Antibody Screening

• HLA Typing

• Cross-matching

• ABO Blood Tests

• Others

Blood Typing Technique Outlook (Revenue, USD Million, 2018 - 2030)

• PCR Based and Microarray Based

• Assay Based Techniques

• Massively Parallel Sequencing

• Other

Blood Typing Application Outlook (Revenue, USD Million, 2018 - 2030)

• Blood Transfusions

• Organ Transplants

• Diagnostic Testing

Blood Typing End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Clinics

• Diagnostic Laboratories

• Blood Banks

• Others

Blood Typing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait
    

List of Key Players in the Blood Typing Market

• Mesa Laboratories, Inc. (Agena Bioscience, Inc.)

• Danaher Corporation (Beckman Coulter)

• Bio-Rad Laboratories, Inc.

• DIAGAST

• Grifols, S.A.

• AXO Science

• Merck KGaA

• Quotient, Ltd.

• Thermo Fisher Scientific

• Immucor, Inc.

• BAG Diagnostics GmbH

• Seegene Inc.